Loading patent…
OwnerMawaheb M. El-Naggar, Shaker A. Mousainventors
Estimating the term…
This invention provides for the treatment of thrombosis through the administration, in combination, of a short or long acting GPIIb/IIIa antagonist (A) and anticoagulant (B) that might include the following: UFH or low molecular weight heparin (LMWH), ultra LMWH, pentasaccharide or direct anti-Xa or direct anti-IX/IXa, direct anti-IIa (thrombin) or tissue factor pathway inhibitor (TFPI) for the prevention and treatment of thromboembolic events associated with arterial or venous thrombosis and other thrombosis-induced processes by any means that produces contact of the agents with their site of action wherein at least one of the components of each of these combinations is given in reduced amount.
A method of treating thromboembolic disorders associated with arterial and venous thrombosis in a mammal comprising administering to said mammal a combination of:
A method for in hospital use of a short acting GPIIb/IIIa antagonists such as tirofiban, integrilin, DUP728 or any other short acting GPIIb/IIIa antagonist, with 2-4 hours half-life after termination of the IV bolus/infusion plus UFH or LMWH or any other short acting anticoagulant from the class of direct anti-Xa, direct anti-IX/IXa, direct anti-IIa or r-TFPI could be used as an IV injectable for the prevention and treatment of thromboembolic events associated with arterial (angina, MI, stroke, peripheral artery diseases) and venous thrombosis (DVT, PE) as a stand alone regimen or in conjunction with other therapies, post-surgery or with interventional procedures.
A method for In-hospital and out-hospital (intravenous, subcutaneous or oral) of a long acting GPIIb/IIIa antagonist (with >4 hours half life after the termination of IV bolus/infusion or SC injection) such as XV454, DMP802, XV459 or Roxifiban with LMWH such as tinzaparin, enoxaparin, dalteparin or any other long acting anticoagulant such as Pentasaccharide, direct anti-Xa, direct anti-IX/IXa, direct anti-IIa or r-TFPI could be used for the prevention and treatment of thromboembolic events associated with arterial and venous thrombosis.
Dependencies are inferred from the claim text.